

July 25, 2016

Press Release

GreenPeptide Co., Ltd.
President & CEO: Kenichi Nagai
(Code: 4594, TSE Mothers)
Inquiries: Teruhiko Sakai, Director/CFO
T E L : 0 3 - 5 8 4 0 - 7 6 9 7

Announcement Concerning Development of Immunoassay
Procedures Outsourced to GreenPeptide

GreenPeptide Co., Ltd. (President & CEO Kenichi Nagai; GreenPeptide) wishes to announce that it has concluded an agreement with Bristol-Myers Squibb K.K. (Shinjuku-ku, Tokyo; President & CEO Davide Piras; BMS) regarding the outsourced development of immunoassay procedures for use in research concerning the efficacy of Orencia®** (Generic name: Abatacept, genetically recombinant), a rheumatoid arthritis agent manufactured and marketed by BMS, as well as regarding the performance of the assay procedure in such research.

■ Background to outsourcing agreement

In recent years, in order to demonstrate the clinical usefulness of cancer peptide vaccines being developed by GreenPeptide, we have developed immunoassay methods using Luminex® 100/200™ system *. The techniques developed for research on cancer immunotherapies will be applied in the development of the immunoassay procedures for use in the research on the rheumatoid arthritis therapy. The high evaluation by BMS of these techniques, our experience with them and the setup for their performance led to the conclusion of the current agreement.

GreenPeptide will actively continue to utilize its proprietary technologies, and work forward to develop pharmaceutical products.

■ Effect on results

In the past, GreenPeptide has been entrusted with the development and performance of assay techniques for pharmaceutical products and antibodies by other companies, and these sales were booked resulting as few percent addition. The sales arising from the conclusion of this agreement will account for a few percent of sales in the year to March



2017 and the effect on results will be minimal.

This agreement will not result in out-licensing.

It will not affect the progress of the company's existing pipeline.

***Luminex® 100/200™ System**

This is an assay system developed by the US company Luminex Corporation, which can simultaneously assay multiple micro-volume samples using various types of micro-beads based on flow cytometry principles. It has been licensed to GreenPeptide by Luminex.

****Orencia**

Orencia is a genetically recombinant version of a soluble fusion protein composing the extracellular domain of human cytotoxic T- lymphocyte-antigen-4 (CTLA-4) and the Fc domain of human IgG1 developed by BMS. It is a biopharmaceutical product that has an improving action on the signs and symptoms of rheumatoid arthritis, physical functions and quality of life by suppressing T-cell activation by binding specifically with CD80

S in December 2005 and is now marketed in over 50 countries worldwide. In Japan, it was approved as an intravenous infusion in July 2010, then as a subcutaneous injection syringe in June 2013 and as a subcutaneous auto-injector formulation in February 2016.

About GreenPeptide

GreenPeptide is a drug discovery venture company engaged in the research and development of cancer immunotherapies that make use of the body's immune system to fight cancer. There are hopes that cancer immunotherapies will be the 4th therapy when surgery, radiotherapy and chemotherapy have failed.

GreenPeptide is actively developing cancer immunotherapy candidates with the aim that they become innovative new cancer treatments.